13.20

0.15% -0.02

After Hours: 13.20

Benitec Biopharma Inc (BNTC)

Overview News Price History Financials Discussions Forecast Stock Split

Benitec Biopharma Inc stock is traded at $13.20, with a volume of 152.60K. It is down -0.15% in the last 24 hours and up +25.12% over the past month. Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Previous Close:

$13.22

Open:

$12.98

24h Volume:

152.60K

Relative Volume:

1.33

Market Cap:

$453.48M

Revenue:

$7,000

Net Income/Loss:

$-41.54M

P/E Ratio:

-14.21

EPS:

-0.929

Net Cash Flow:

$-20.57M

1W Performance:

+3.94%

1M Performance:

+25.12%

6M Performance:

+10.09%

1Y Performance:

+0.23%

1-Day Range:

$12.32

$13.84

1-Week Range:

$12.32

$13.84

52-Week Range:

$9.85

$16.76

Benitec Biopharma Inc Stock (BNTC) Company Profile

Name

Benitec Biopharma Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(510) 780-0819

Address

3940 TRUST WAY, HAYWARD, CA

Employee

Twitter

@BenitecLtd

Next Earnings Date

2026-05-13

Latest SEC Filings

BNTC's Discussions on Twitter

Compare BNTC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BNTC Benitec Biopharma Inc	13.20	459.66M	7,000	-41.54M	-20.57M	-0.929
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-07-25	Initiated	TD Cowen	Buy
Dec-16-24	Initiated	H.C. Wainwright	Buy
Dec-13-24	Initiated	Robert W. Baird	Outperform
Oct-16-24	Initiated	Oppenheimer	Outperform
Sep-12-24	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Leerink Partners	Outperform
Jun-13-24	Initiated	Piper Sandler	Overweight
Oct-05-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-20-20	Initiated	Ladenburg Thalmann	Buy
Feb-26-16	Downgrade	Maxim Group	Buy → Hold
Dec-31-15	Reiterated	Maxim Group	Buy
Sep-16-15	Reiterated	Maxim Group	Buy

View All

Benitec Biopharma Inc Stock (BNTC) Latest News

Jun 30, 2026

Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com - Investing.com South Africa

Jun 30, 2026

Responsive Playbooks and the BNTC Inflection - Stock Traders Daily

Jun 30, 2026

Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund - Stock Titan

Jun 30, 2026

Jun 29, 2026

BNTC Stock Price, Quote & Chart - ChartMill

Jun 29, 2026

Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026